Merck & Co., Inc. is a global healthcare company that develops and manufactures pharmaceuticals, vaccines, biologics, and animal health products. Its core products include treatments for cancer, diabetes, and infectious diseases, with significant revenue generated from its oncology and vaccine segments. The company also focuses on research and development to innovate new therapies and improve existing ones.
The stock presents a balanced investment profile, appealing to investors seeking a combination of growth and income through dividends. With a moderate dividend yield and a focus on innovation, it may attract those interested in stable returns while also considering potential capital appreciation.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-27 | Hold | Buy | Strong momentum and solid fundamentals support growth potential. |
| 2026-06-19 | Buy | Hold | Weak momentum and fundamentals suggest caution. |
| 2026-06-09 | Hold | Buy | Stable dividend, moderate growth, cautious market sentiment. |
| 2026-06-01 | Buy | Hold | Solid dividend yield, but mixed momentum signals. |
| 2026-05-24 | Hold | Buy | Strong momentum and solid dividend yield support growth. |
| 2026-05-08 | — | Hold | Mixed performance; cautious outlook amid market volatility. |
| 2026-05-05 | Hold | Buy | Компания Merck демонстрирует сильный рост за последние 120 дней и стабильную дивидендную доходность. Несмотря на недавние колебания доходов, потенциал для роста остается высоким благодаря инновациям в области здравоохран |
| 2026-04-27 | Buy | Hold | Компания Merck демонстрирует стабильный рост в долгосрочной перспективе, однако недавние колебания цен и снижение выручки указывают на определенные риски в краткосрочной перспективе. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-10 | HSBC | Target Raised | 150 → 172 | 147.6 |
| 2026-09-09 | Leerink Partners | Target Raised | 127 → 161 | 148.49 |
| 2026-09-08 | Guggenheim | Target Raised | — → 170 | 150.34 |
| 2026-09-04 | Wells Fargo | Target Raised | 150 → 170 | 152.34 |
| 2026-08-25 | Argus Research | Target Raised | 145 → 170 | 153.61 |
| 2026-08-25 | Wolfe Research | Target Raised | 155 → 180 | 150.69 |
| 2026-08-21 | Goldman Sachs | Target Raised | 140 → 160 | 149.25 |
| 2026-08-20 | BMO Capital | Target Raised | 142 → 170 | 149.64999 |
| 2026-08-20 | UBS | Target Raised | 145 → 175 | 152.22 |
| 2026-08-20 | RBC Capital | Rating Downgraded | — → 150 | 152.22 |
| 2026-08-20 | UBS | Update | — → 150 | 152.22 |
| 2026-08-19 | Morgan Stanley | Rating Upgraded | — → 179 | 152.22 |
| 2026-08-12 | Daiwa | Update | — → 143 | 130.45 |
| 2026-08-11 | Argus Research | Target Raised | — → 145 | 130.9 |
| 2026-08-05 | Morgan Stanley | Target Raised | 113 → 116 | 130.39999 |
| 2026-08-05 | Guggenheim | Target Raised | 145 → 146 | 128.04 |
| 2026-07-29 | Barclays | Target Raised | 140 → 150 | 131.835 |
| 2026-07-27 | Bernstein | Target Raised | — → 105 | 132.34 |
| 2026-07-13 | BMO Capital | Target Raised | — → 142 | 124.08 |
| 2026-07-13 | Guggenheim | Target Raised | — → 145 | 123.54 |
| 2026-07-06 | HSBC | Target Raised | 135 → 150 | 126.05 |
| 2026-06-30 | Jefferies | Target Raised | — → 141 | 129.38 |
| 2026-06-29 | Scotiabank | Target Raised | 136 → 155 | 129.38 |
| 2026-06-02 | Guggenheim | Update | — → 140 | 115.21 |
| 2026-05-01 | Morgan Stanley | Target Raised | 109 → 112 | 112.47 |
| 2026-03-12 | Wells Fargo | Target Raised | — → 150 | 116.22 |
| 2026-02-24 | RBC Capital | Update | — → 142 | 123.93 |
| 2026-02-13 | Deutsche Bank | Rating Upgraded | — → 150 | 121.53 |
| 2026-02-04 | Goldman Sachs | Target Raised | 120 → 133 | 115.86 |
| 2026-02-04 | BMO Capital | Target Raised | 130 → 135 | 115.86 |
| 2026-02-04 | Bernstein | Target Raised | 95 → 100 | 115.86 |
| 2026-02-03 | Scotiabank | Target Raised | 120 → 136 | 116.37 |
| 2026-01-27 | Cantor Fitzgerald | Target Raised | 83 → 116 | 107.4 |
| 2026-01-08 | Wolfe Research | Rating Upgraded | — → 135 | 108.59 |
